Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 AUD | -.--% | -.--% | -.--% |
03-05 | Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results | MT |
02-27 | Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 4
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Clinical-stage Life Sciences
100.0
%
| 3 | 100.0 % | 4 | 100.0 % | +24.70% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 3 | 100.0 % | 4 | 100.0 % | +24.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thian Chew
CEO | Chief Executive Officer | - | 30/11/17 |
Melanie Leydin
DFI | Director of Finance/CFO | 51 | 12/07/20 |
Brendon Lau
IRC | Investor Relations Contact | - | - |
Corporate Secretary | - | 31/10/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 21/10/20 | |
Thian Chew
CEO | Chief Executive Officer | - | 30/11/17 |
Alan Yamashita
BRD | Director/Board Member | 74 | 11/02/19 |
Rob Merriel
BRD | Director/Board Member | - | 30/08/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,421,632,206 | 3,271,816,919 ( 50.95 %) | 0 | 50.95 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-.--% | 20.86M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- IVX Stock
- Company Invion Limited